American Journal of Cardiology
Volume 101, Issue 9 , Pages 1232-1238, 1 May 2008

Relation of Hyperemic Epicardial Flow to Outcomes Among Patients With ST-Segment Elevation Myocardial Infarction Receiving Fibrinolytic Therapy

  • C. Michael Gibson, MS, MD

      Affiliations

    • TIMI Study Group, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: 617-278-0145; fax: 617-734-7329.
  • ,
  • Yuri B. Pride, MD

      Affiliations

    • Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • Jacqueline L. Buros, BA

      Affiliations

    • TIMI Study Group, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • Vijayalakshmi Kunadian, MBBS, MD, MRCP

      Affiliations

    • TIMI Study Group, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • Matthew C. Southard, BS

      Affiliations

    • TIMI Study Group, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • Caitlin J. Harrigan, BA

      Affiliations

    • TIMI Study Group, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • Lauren N. Ciaglo, BA

      Affiliations

    • TIMI Study Group, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • Marc S. Sabatine, MD, MPH

      Affiliations

    • TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • ,
  • Christopher P. Cannon, MD

      Affiliations

    • TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • ,
  • Eugene Braunwald, MD

      Affiliations

    • TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Received 12 August 2007; received in revised form 27 December 2007; accepted 27 December 2007. published online 06 March 2008.

In patients with ST-segment elevation myocardial infarction (STEMI), the restoration of normal epicardial flow following fibrinolytic administration is associated with improved clinical outcomes. The goal of this analysis was to examine the relation between hyperemic flow and outcomes following fibrinolytic administration for STEMI. In Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis In Myocardial Infarction 28 (CLARITY-TIMI 28), patients with STEMI (n = 3,491) treated with fibrinolytic therapy were scheduled to undergo angiography 48 to 192 hours after randomization. Corrected TIMI frame count (CTFC) and TIMI myocardial perfusion grade (TMPG) were assessed, and their associations with outcomes at 30 days were evaluated. When evaluating initial angiography of the infarct-related artery, there was a nearly linear relation between CTFC and 30-day mortality, with faster flow (lower CTFC) associated with improved outcomes. Conversely, in patients who underwent percutaneous coronary intervention (PCI), very fast flow (CTFC <14) after intervention was associated with worse outcomes. Post-PCI hyperemic flow (CTFC <14) was associated with a higher incidence of mortality (p = 0.056), recurrent myocardial infarction (p = 0.011), and a composite of death or myocardial infarction (p <0.001) compared with normal flow (CTFC 14 to 28). When post-PCI CTFC was further stratified by TMPG, there was a U-shaped relation between mortality and CTFC in patients with poor myocardial perfusion (TMPG 0 or 1). This relation appeared to be linear in patients with TMPG 2 or 3. In conclusion, in patients who undergo PCI after fibrinolytic therapy for STEMI, hyperemic flow on coronary angiography is associated with an increased incidence of adverse outcomes. Hyperemic flow with associated impaired myocardial perfusion may be a marker of more extensive downstream microembolization.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was supported in part by a grant from Sanofi-Aventis, Paris, France, and Bristol-Myers Squibb, Princeton, New Jersey.

PII: S0002-9149(08)00047-7

doi:10.1016/j.amjcard.2007.12.023

American Journal of Cardiology
Volume 101, Issue 9 , Pages 1232-1238, 1 May 2008